Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tianjin JuveStar Biotech
Tianjin, Tianjin, China
- Ownership
- Private
- Development stage
- Other
01
Overview
RZL-012, an injectable small molecule lipolytic drug licensed from Raziel Therapeutics, has completed Phase 2a in the US with significant improvement in chin appearance and good safety, and a Phase 3 registration trial for submental fat reduction is being initiated in China with expected launch in 2027 in Greater China.
- Therapeutic areas
- Rare DiseasesDermatologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Raziel Therapeutics: exclusive license for RZL-012 in mainland China, Hong Kong, Macau, and Taiwan; JuveStar responsible for Phase 3 clinical studies and commercialization in Greater China, Raziel responsible for manufacturing drug substance and finished product.Fosun Pharma / Fosun Health Capital: JuveStar is invested and incubated by Fosun’s venture capital arm as part of Fosun’s medical aesthetic platform.
Beyond the preview
Go deeper on Tianjin JuveStar Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin JuveStar Biotech.